Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,301 papers from all fields of science
Search
Sign In
Create Free Account
North Central Cancer Treatment Group
Known as:
NCCTG
A national clinical research group sponsored by the NCI. The research base for NCCTG is located at Mayo Clinic in Rochester, Minn. NCCTG consists of…
Expand
National Institutes of Health
Create Alert
Alert
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A novel approach of longitudinal adverse event evaluation in oncology clinical trials: the Toxicity over Time (ToxT) analysis of clinical trials N9741 and 979254 (Alliance)
G. Thanarajasingam
,
P. Atherton
,
P. Novotny
,
C. Loprinzi
,
J. Sloan
,
A. Grothey
The Lancet Oncology
2016
Corpus ID: 206142684
Highly Cited
2008
Highly Cited
2008
Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of…
D. Sargent
,
S. Marsoni
,
+7 authors
S. Gallinger
2008
Corpus ID: 74152472
4008 Background: Patients (pts) with CC demonstrating high-frequency MSI (MSI-H) have a stage-independent improved survival…
Expand
2008
2008
Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG…
D. Nikcevich
,
A. Grothey
,
+7 authors
C. Loprinzi
2008
Corpus ID: 74012285
4009 Background: Cumulative sNT is the dose-limiting toxicity of oxaliplatin which commonly leads to early discontinuation of…
Expand
2008
2008
A Dose-Escalation Study of Aerosolized Sargramostim in the Treatment of Metastatic Melanoma: An NCCTG Study
S. Markovic
,
V. Suman
,
+7 authors
M. Pittelkow
American Journal of Clinical Oncology
2008
Corpus ID: 19972484
Objectives:Early testing of aerosolized sargramostim therapy demonstrated anecdotal clinical responses in patients with…
Expand
Review
2005
Review
2005
Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial
E. Perez
,
V. Suman
,
+8 authors
A. Jaffe
2005
Corpus ID: 56664315
556 Background: NCCTG N9831 is a 3-arm randomized Phase III trial comparing safety and efficacy of AC followed by weekly…
Expand
2005
2005
A Phase II Trial of Docetaxel and Carboplatin as First-Line Chemotherapy for Metastatic Breast Cancer: NCCTG Study N9932
E. Perez
,
V. Suman
,
+7 authors
F. Addo
Oncology
2005
Corpus ID: 33443835
Objective: A phase II multi-institutional clinical trial conducted to evaluate the efficacy and tolerability of docetaxel and…
Expand
Review
1999
Review
1999
A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.
M. Prados
,
C. Scott
,
+9 authors
W. Curran
International Journal of Radiation Oncology…
1999
Corpus ID: 34163814
Review
1998
Review
1998
A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de…
A. de Gramont
,
C. Louvet
,
T. André
,
C. Tournigand
,
M. Krulik
European Journal of Cancer
1998
Corpus ID: 22841335
1997
1997
Utility of screening procedures for detecting recurrence of disease after complete response in patients with small cell lung carcinoma
E. Perez
,
C. Loprinzi
,
J. Sloan
,
David T. Owens
,
P. Novotny
,
J. Bonner
Cancer
1997
Corpus ID: 37400932
Studies evaluating the efficacy of routine follow‐up testing in detecting disease recurrence in treated lung carcinoma patients…
Expand
1996
1996
North Central Cancer Treatment Group (NCCTG).
C. Loprinzi
Journal of the National Cancer Institute…
1996
Corpus ID: 44833713
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE